EXAS
Exact Sciences Corporation·Healthcare
104.91
0.000%(+0.00)
Close PriceLast Updated: — ET
52W L: $38.8152W H: $104.98
EXAS NEWS
proactiveinvestors.com
Apr 16
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag
Shares of Abbott Laboratories (NYSE:ABT) fell 3.2% on Thursday morning after the healthcare conglomerate marginally beat Wall Street estimates for quarterly profit and revenue, but flagged a hit to its 2026 earnings outlook from its recently completed cancer diagnostics acquisition. Investors weighed near-term earnings strength against dilution from the company's roughly $23 billion acquisition of Exact Sciences.
defenseworld.net
Apr 6
96,685 Shares in Exact Sciences Corporation $EXAS Purchased by Capricorn Fund Managers Ltd
Capricorn Fund Managers Ltd acquired a new stake in shares of Exact Sciences Corporation (NASDAQ: EXAS) during the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 96,685 shares of the medical research company's stock, valued at approximately $9,819,000. Exact Sciences makes up about 2.4% of Capricorn Fund
defenseworld.net
Apr 4
Exact Sciences Corporation $EXAS Shares Sold by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC cut its stake in Exact Sciences Corporation (NASDAQ: EXAS) by 39.6% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,044 shares of the medical research company's stock after selling 5,932 shares during the quarter. Exchange
defenseworld.net
Apr 3
FNY Investment Advisers LLC Buys Shares of 28,500 Exact Sciences Corporation $EXAS
FNY Investment Advisers LLC acquired a new position in shares of Exact Sciences Corporation (NASDAQ: EXAS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 28,500 shares of the medical research company's stock, valued at approximately $2,894,000. Exact Sciences accounts for about
defenseworld.net
Apr 3
Banque Pictet & Cie SA Lowers Position in Exact Sciences Corporation $EXAS
Banque Pictet and Cie SA decreased its stake in Exact Sciences Corporation (NASDAQ: EXAS) by 77.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,415 shares of the medical research company's stock after selling 151,772 shares
businesswire.com
Mar 17
Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze tri.
